CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Science Press and Elsevier Country of Publication: China NLM ID: 101197608 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-3244 (Electronic) Linking ISSN: 16720229 NLM ISO Abbreviation: Genomics Proteomics Bioinformatics Subsets: MEDLINE
    • Publication Information:
      Original Publication: Beijing, China : Science Press and Elsevier
    • Subject Terms:
      Asian People/*genetics ; Cytochrome P-450 CYP2A6/*genetics ; Organoplatinum Compounds/*therapeutic use ; Oxonic Acid/*therapeutic use ; Stomach Neoplasms/*drug therapy ; Tegafur/*therapeutic use; Adult ; Aged ; China ; Diarrhea/etiology ; Diarrhea/pathology ; Drug Combinations ; Drug Therapy, Combination ; Female ; Genotype ; Haplotypes ; Humans ; Kaplan-Meier Estimate ; Linkage Disequilibrium ; Male ; Middle Aged ; Odds Ratio ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Oxonic Acid/adverse effects ; Polymorphism, Genetic ; Prospective Studies ; Severity of Illness Index ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Tegafur/adverse effects ; Treatment Outcome
    • Abstract:
      Gastric carcinoma is a heterogeneous malignant disease involving genetic factors. To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment. Clinical data on 60 consecutive gastric cancer patients receiving SOX regimen were collected prospectively. We sequenced all exons of CYP2A6 and a total of 22 different polymorphisms were detected in the present study. Comprehensive analyses of these genetic polymorphisms were performed to determine their association with both safety and efficacy of SOX regimen. Our results showed that polymorphisms of CYP2A6 were associated with the safety and efficacy of SOX treatment. Among them, missense mutations CYP2A6 rs60823196 and rs138978736 could be possible risk factors (P<0.05) for severe diarrhea induced by SOX, whereas CYP2A6 rs138978736 could be a conceivable predictor for overall survival of patients treated with SOX adjuvant chemotherapy. Further large-scale randomized prospective studies are warranted to confirm these findings.
      (Copyright © 2017. Production and hosting by Elsevier B.V.)
    • References:
      Pharmacogenetics. 2001 Jun;11(4):317-23. (PMID: 11434509)
      Clin Cancer Res. 2000 Nov;6(11):4409-15. (PMID: 11106261)
      Cancer Res Treat. 2013 Mar;45(1):1-14. (PMID: 23613665)
      Gastric Cancer. 2017 Jan;20(1):146-155. (PMID: 26715117)
      Ann Oncol. 2015 Jan;26(1):141-8. (PMID: 25316259)
      Br J Cancer. 2011 Mar 29;104(7):1126-34. (PMID: 21364592)
      Ann Transl Med. 2014 Jul;2(7):61. (PMID: 25333036)
      Clin Pharmacol Ther. 2006 Sep;80(3):282-97. (PMID: 16952495)
      Bioinformatics. 2000 Feb;16(2):182-3. (PMID: 10842743)
      Lancet Oncol. 2008 Mar;9(3):215-21. (PMID: 18282805)
      Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):745-55. (PMID: 19442035)
      Cancer Sci. 2008 May;99(5):1049-54. (PMID: 18380793)
      Oncol Lett. 2015 Mar;9(3):1451-1457. (PMID: 25663930)
      Int J Oncol. 1998 Oct;13(4):693-8. (PMID: 9735397)
      Gastric Cancer. 2016 Apr;19(2):586-96. (PMID: 25851942)
      Cancer Res. 1996 Jun 1;56(11):2602-6. (PMID: 8653704)
      Biomed Pharmacother. 2003 Nov;57(9):412-5. (PMID: 14652166)
      Bioinformatics. 2005 Jan 15;21(2):263-5. (PMID: 15297300)
      FEBS Lett. 1999 Oct 29;460(2):321-7. (PMID: 10544257)
      N Engl J Med. 2007 Nov 1;357(18):1810-20. (PMID: 17978289)
      Bull Cancer. 2000 Dec;87(12):881-6. (PMID: 11174117)
      Chin Med J (Engl). 2013;126(18):3470-4. (PMID: 24034092)
      Ann Oncol. 2003;14 Suppl 2:ii31-6. (PMID: 12810455)
      Pharmacogenet Genomics. 2005 Mar;15(3):189-92. (PMID: 15861044)
      Mol Clin Oncol. 2014 Jan;2(1):93-98. (PMID: 24649314)
      Cell Mol Life Sci. 2002 Nov;59(11):1914-27. (PMID: 12530522)
      CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
      JAMA. 2010 May 5;303(17):1729-37. (PMID: 20442389)
      Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):371-82. (PMID: 22288606)
      Eur J Cancer. 2012 Mar;48(4):518-26. (PMID: 22243774)
      Biochem Pharmacol. 1982 Sep 15;31(18):3006-8. (PMID: 6814451)
      Pharmacogenetics. 2002 Jun;12 (4):299-306. (PMID: 12042667)
      Gastric Cancer. 2016 Jul;19(3):919-26. (PMID: 26474989)
    • Contributed Indexing:
      Keywords: CYP2A6; Gastric cancer; Pharmacogenomics; Polymorphism; SOX
    • Accession Number:
      0 (Drug Combinations)
      0 (Organoplatinum Compounds)
      04ZR38536J (Oxaliplatin)
      150863-82-4 (S 1 (combination))
      1548R74NSZ (Tegafur)
      5VT6420TIG (Oxonic Acid)
      EC 1.14.14.1 (Cytochrome P-450 CYP2A6)
    • Publication Date:
      Date Created: 20170817 Date Completed: 20171219 Latest Revision: 20221207
    • Publication Date:
      20240829
    • Accession Number:
      PMC5582793
    • Accession Number:
      10.1016/j.gpb.2016.11.004
    • Accession Number:
      28811232